Nanocarrier-Based Management of Venous and Arterial Thrombosis

Cardiovascular diseases represent the leading cause of mortality worldwide, with recent epidemiological studies revealing an increasing trend of prevalence and incidence globally. Among cardiovascular disorders, both arterial and venous thrombosis and particularly their acute life-threating complica...

Full description

Saved in:
Bibliographic Details
Published in:Crystals (Basel) 2022-04, Vol.12 (4), p.450
Main Authors: Haba, Mihai Ștefan Cristian, Șerban, Dragomir N., Șerban, Ionela Lăcrămioara, Tudorancea, Ivona Maria, Haba, Raluca Maria, Mărănducă, Minela Aida, Tănase, Daniela Maria, Iliescu, Radu, Tudorancea, Ionuț
Format: Article
Language:English
Subjects:
Anticoagulants
arterial thrombosis
Biomarkers
Blood clots
Chronic illnesses
Heart attacks
Heart failure
Hemorrhage
Injury prevention
Ligands
Magnetic properties
Magnetic resonance imaging
Medical diagnosis
Molecular structure
Mortality
nanocarriers
Nanoparticles
Nanotechnology
Pathophysiology
Peptides
Polyethylene glycol
Pulmonary arteries
Pulmonary embolisms
Thromboembolism
Thrombosis
Tomography
Trauma
Veins & arteries
venous thrombosis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cardiovascular diseases represent the leading cause of mortality worldwide, with recent epidemiological studies revealing an increasing trend of prevalence and incidence globally. Among cardiovascular disorders, both arterial and venous thrombosis and particularly their acute life-threating complications such as ischemic stroke, acute myocardial infarction, deep venous thrombosis and pulmonary embolism are responsible for more than 25% of all deaths worldwide. The modern approach following progresses in anticoagulant, thrombolytic and antiaggregant therapies has significantly improved the prognoses of these conditions in the last past decades. However, several challenges still remain such as achieving the optimal drug concentration at the injured site, reducing the shortcomings of drug resistance and the incidence of life-threatening hemorrhages. Nanomedicine is a well-known field of medicine in which atomic and molecular structures ranging between 0.1–100 nm are used in various domains due to their specific mechanical, electrical, thermal and magnetic properties. Recent experimental and clinical evidence have shown that nanotechnology could be a safe, effective and an appealing approach for various non-cardiovascular and cardiovascular diseases such as thromboembolic conditions. In this review, we have described the most promising nanotechnology-based approaches not only for the diagnosis, but also for the treatment of vascular thrombotic diseases.
ISSN:2073-4352
2073-4352
DOI:10.3390/cryst12040450